Topotecanum [Inn-Latin] en es it fr

Topotecanum [Inn-Latin] Brand names, Topotecanum [Inn-Latin] Analogs

Topotecanum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Topotecanum [Inn-Latin] Chemical_Formula


Topotecanum [Inn-Latin] RX_link

Topotecanum [Inn-Latin] fda sheet

Topotecanum_[Inn-Latin] FDA

Topotecanum [Inn-Latin] msds (material safety sheet)

Topotecanum_[Inn-Latin] MSDS

Topotecanum [Inn-Latin] Synthesis Reference

No information avaliable

Topotecanum [Inn-Latin] Molecular Weight

421.446 g/mol

Topotecanum [Inn-Latin] Melting Point

213-218 oC

Topotecanum [Inn-Latin] H2O Solubility

1 mg/ml

Topotecanum [Inn-Latin] State


Topotecanum [Inn-Latin] LogP


Topotecanum [Inn-Latin] Dosage Forms

Powder for solution

Topotecanum [Inn-Latin] Indication

For the treatment of metastatic carcinoma of the ovary and small cell lung cancer following the failure of first-line chemotherapy.

Topotecanum [Inn-Latin] Pharmacology

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug.

Topotecanum [Inn-Latin] Absorption

No information avaliable

Topotecanum [Inn-Latin] side effects and Toxicity

The primary anticipated complication of overdosage would consist of bone marrow suppression.

Topotecanum [Inn-Latin] Patient Information

No information avaliable

Topotecanum [Inn-Latin] Organisms Affected

Humans and other mammals